D, L-Hopantenic acid (Acidum hopantenicum-D, L)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Nootropics

Included in the formulation
  • Pantogam asset
    capsules inwards 
    PIK-PHARMA, LLC     Russia
    • АТХ:

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    Affects GABAB-receptor-channel complex. Strengthens energy processes, increases oxygen consumption of tissues, normalizes blood supply, promotes the utilization of glucose in the brain. Improves thinking, dynamics of nervous processes in the brain, memory, has anticonvulsant activity and anti-anxiety action. Reduces motor excitability, organizes behavior. It causes inhibition of the pathological activity of the cystic reflex and detrusor tone.

    Pharmacokinetics:

    After oral administration, it is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 1 hour.

    Not exposed to metabolism. Penetrates through the blood-brain barrier. Elimination by the kidneys (70%) and with feces (30%) unchanged after 24 hours.

    Indications:

    It is used to treat cognitive disorders with organic brain lesions, cerebrovascular insufficiency, extrapyramidal hyperkinesis (including those caused by taking neuroleptics). Used in the complex therapy of epilepsy and schizophrenia, with psychoemotional stresses, decreased concentration and memory, neurogenic disorders of urination.

    ICD-10

    V.F20-F29.F20   Schizophrenia

    V.F40-F48.F48.9   Neurotic disorder, unspecified

    VI.G00-G09.G09   Consequences of inflammatory diseases of the central nervous system

    VI.G10-G13.G10   Huntington's disease

    VI.G20-G26.G20   Parkinson's disease

    VI.G20-G26.G21.8   Other forms of secondary parkinsonism

    VI.G40-G47.G40   Epilepsy

    IX.I60-I69.I67.9   Cerebrovascular disease, unspecified

    V.F90-F98.F90   Hyperkinetic disorders

    V.F90-F98.F90.8   Other hyperkinetic disorders

    XVIII.R30-R39.R32   Urinary incontinence, unspecified

    XVIII.R30-R39.R35   Polyuria

    XVIII.R30-R39.R39.1   Other difficulties associated with urination

    XVIII.R40-R46.R45.7   Condition of emotional shock and stress, unspecified

    XVIII.R50-R69.R53   Malaise and fatigue

    XIX.T36-T50.T43.3   Poisoning with antipsychotic and antipsychotics

    XIX.T90-T98.T90.5   Consequences of intracranial injury

    XXI.Z70-Z76.Z73.6   Limitations of activities caused by a decrease or loss of ability to work

    Contraindications:

    Acute renal failure, individual intolerance.

    Carefully:

    Presence of allergic reactions in the anamnesis.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in the first trimester of pregnancy and lactation.

    Dosing and Administration:

    Children

    Inside, depending on age:

    up to 1 year: 300 mg per day;

    1-3 years: 600 mg per day;

    3-15 years: 900 mg per day.

    Adults

    Inside after eating 300-900 mg (1-3 capsules) 2-3 times a day.

    The highest daily dose: 2.4 g (8 capsules).

    The highest single dose: 900 mg (3 capsules).

    Side effects:

    Central and peripheral nervous system: agitation, insomnia or drowsiness, hallucinations.

    Sense organs: rhinitis, conjunctivitis.

    Dermatological reactions: skin rashes.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    Strengthens the effectiveness of anticonvulsants, prolongs the action of barbiturates.

    Simultaneous use with glycine and xyliphon enhances the therapeutic effect of the drug.

    Prevents side effects of neuroleptics, finlepsin, phenobarbital.

    Special instructions:

    It is not recommended to take the drug before bedtime.

    Instructions
    Up